New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...
Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...
Patients enrolled on the Children's Oncology Group neuroblastoma biology study ANBL00B1 (ClinicalTrials.gov identifier: NCT00904241) who received care at the University of Chicago (UChicago) or the ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer's drug—are poised ...
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
It’s widely known that artificial intelligence (AI) is profoundly reshaping the healthcare industry. Hospitals have used AI in a variety of ways, from streamlining workflows to aiding in bedside ...
Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback